Scientist, Mechanistic Biology

The role

A mechanistic biologist will work with Platform and Chemistry Teams to drive mechanistic understanding of lead compounds. The role involves supporting core drug discovery efforts and elucidating novel pharmacological mechanisms of next-gen IPMs.

What you will do

• Design and execute mechanistic studies on hit compounds
• Dissect signaling pathways to map compound mechanism of action
• Interrogate protein-protein interactions
• Prepare and analyze NGS libraries
• Develop and deploy functional cell-based assays to characterize novel pharmacology

Required qualifications

• BS, MS or PhD in Cell Biology, Biochemistry, or related field
• Candidates without a PhD should have 5-7+ years of relevant industry experience
• Previous experience elucidating novel biology underlying small-molecule mechanism of action in a drug discovery context
• Top-notch written and oral communication skills
• Experience with cellular and molecular biology, including mammalian cell line work and associated assays, stable cell line generation (lentiviral and CRISPR-based systems), co-IP/pull-down assays, RNA
• Experience with small molecule drug development campaigns (hit discovery, hit validation, dose-response studies, SAR and MOA studies)
• Experience with mechanistic studies of cell signaling, pathway analysis, and PTM analysis
• Experience with protein-protein interaction techniques (e.g., BRET, APEX/BioID, AlphaScreen, etc.)
• Experience with NGS library prep, sequencing, and analysis

Nice to have

• Experience with PROTAC/next-gen IPM technologies
• Experience working at the interface of mechanistic biology and chemistry
• Experience working on teams that have successfully advanced research to the clinic
• Experience managing CROs

Benefits

• Strong equity incentives
• Top tier medical, dental, and vision coverage
• One Medical membership
• 401(k) retirement plans
• Education and health/fitness incentive programs
• Meditation retreats
• Reading budget

About the company

General Proximity is a seed-stage startup developing the next generation of induced proximity medicines (IPMs). The company uses an OmniTAC drug discovery engine to furnish molecules that co-opt existing cellular machinery.